Clinical trials with anti-angiogenic agents in hematological malignancies

Table 1 Selection of clinical trials and approved anti-angiogenic therapies in hematological malignancies

Drug	Target	Study entities	Approved for
Receptor tyrosine kinase inhibitors
PTK787/ZK 222584 (Vatalanib^®)	VEGFR1-3, PDGFRβ, c-Kit	AML, PMF, MDS, CML, DLBCL, MM
SU5416 (Semaxinib)	VEGFR1-2, c-kit, Flt3	AML, MDS, MM, MPN
Sorafenib (Nexavar^®)	VEGFR2-3, B-Raf, Faf-1, PDGFRβ	AML, ALL, MDS, CML, CLL, NHL, MM	Advanced renal cell carcinoma, HCC
Sunitinib (Sutent^®)	VEGFR1-3, PDGFRα+β, c-kit, Flt3	AML, MDS, CLL, Myeloma, NHL	Advanced renal cell carcinoma, GIST
PKC-412 (Midostaurin)	VEGFR2, PKC, PDGFR, Flt3, c-Kit	AML
Cediranib (Recentin^®)	VEGFR1-3, PDGFRβ, c-Kit	AML, MDS, CLL
Proteasome inhibitors
Bortezomib (Velcade^®)	26S proteasome, NF-κB	AML, ALL, MDS, CML, NHL, MCL	MM, MCL
Anti-VEGF strategies
Bevacizumab (Avastin^®)	VEGF-A	AML, MDS, CLL, CML, NHL, MM	Metastatic colorectal cancer, NSCLC, breast cancer
Immunomodulatory drugs
Thalidomide	bFGF, VEGF, IL-6	AML, MDS, MPN, CLL, NHL, MM	MM
Lenalidomide (Revlimid^®)	bFGF, VEGF, IL-6	AML, MDS, CLL, NHL	MM, 5q- MDS

AML, acute myeloid leukemia; bFGF, basic fibroblast growth factor; DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; IL-6, Interleukin-6; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; VEGF, vascular endothelial growth factor.